In its 2018/19 annual report, the MHRA highlights its preparations for Brexit and reports on its successes in hitting its targets for assessment of medicines.
The Medicines and Healthcare products Regulatory Agency (MHRA) shows in its report how it has progressed against its Corporate Plan 2018-23, the strategic aims of which were:
- Public health and partnerships
- Enhancing innovation
- Proactive, robust surveillance
- Secure global supply chains
- Organisational excellence/efficiency
Detailed statistics are available in the report showing, for example, that 100% of Type IB and Type II variations scientific validation processes were completed within 14 days, and 99% of UK-only marketing authorisation applications were assessed within 150 days.
The MHRA also explains its approach to Brexit over the last year, with the Chief Executive stating:
“Throughout, the Agency has prepared for two models for the post-Brexit regulation of medicines and medical devices – one in which we continue to operate in partnership of some form with the European regulatory network; another in which we would be a standalone regulatory Agency outside European procedures, with the opportunity to develop new partnerships with other countries.”